𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Specific active immunotherapy for primary melanoma: Experience with 5399 Patients

✍ Scribed by R. White; P. Mosca; W. Stanley; J. Johnson; D. S. Tyler; H. F. Seigler

Book ID
110547659
Publisher
Springer
Year
2004
Tongue
English
Weight
293 KB
Volume
11
Category
Article
ISSN
1068-9265

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Overview of melanoma vaccines: Active sp
Overview of melanoma vaccines: Active specific immunotherapy for melanoma patients
✍ David W. Ollila; Mark C. Kelley; Guy Gammon; Donald L. Morton πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 96 KB πŸ‘ 2 views

Although a phase III trial has yet to show a statistically significant improvement in the disease-free or overall survival of melanoma patients receiving vaccine therapy, several phase II trials have shown enhanced disease-free and overall survival of patients who develop a humoral and/or cellular r

Active specific immunotherapy with polyv
Active specific immunotherapy with polyvalent melanoma cell vaccine for patients with in-transit melanoma metastases
✍ Eddy C. Hsueh; Larry Nathanson; Leland J. Foshag; Richard Essner; J. Anne Nizze; πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 341 KB πŸ‘ 2 views

## BACKGROUND. This study was conducted to document the rate, duration, and type of objective response to active specific immunotherapy with a polyvalent melanoma cell vaccine (PMCV) for patients with in-transit melanoma metastases and to identify any acute or chronic toxic effects of PMCV treatme